Target Validation Information
TTD ID	T52389
Target Name	Quinone reductase 1 (NQO1)
Type of Target	Clinical trial
Drug Potency against Target	Apaziquone	Drug Info	IC50 = 69 nM	[6]
	2-Benzyl-1-hydroxy-3H-benzo[f]chromen-3-one	Drug Info	IC50 = 465 nM	[3]
	3-(3,4-Dimethylbenzyl)-4-hydroxy-2H-chromen-2-one	Drug Info	IC50 = 1600 nM	[3]
	3-Benzyl-4-hydroxy-2H-benzo[h]chromen-2-one	Drug Info	IC50 = 880 nM	[3]
	3-Benzyl-4-hydroxy-2H-chromen-2-one	Drug Info	IC50 = 3200 nM	[3]
	3-Benzyl-4-hydroxy-6,7-dimethyl-2H-chromen-2-one	Drug Info	IC50 = 660 nM	[3]
	4-amino-2H-chromen-2-one	Drug Info	IC50 = 13000 nM	[2]
	4-Hydroxy-3-(1-naphthylmethyl)-2H-chromen-2-one	Drug Info	IC50 = 1522 nM	[3]
	4-Hydroxy-3-(2-naphthylmethyl)-2H-chromen-2-one	Drug Info	IC50 = 1452 nM	[3]
	Ethyl Bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate	Drug Info	IC50 = 1221 nM	[3]
	NSC-106080	Drug Info	IC50 = 3000 nM	[4]
	NSC-106547	Drug Info	IC50 = 10000 nM	[1]
	NSC-2113	Drug Info	IC50 = 3500 nM	[1]
	NSC-224124	Drug Info	IC50 = 12500 nM	[1]
	NSC-275420	Drug Info	IC50 = 3000 nM	[1]
	NSC-316158	Drug Info	IC50 = 17500 nM	[1]
	NSC-339580	Drug Info	IC50 = 3000 nM	[1]
	NSC-339583	Drug Info	IC50 = 2000 nM	[1]
	NSC-354279	Drug Info	IC50 = 2000 nM	[1]
	NSC-621351	Drug Info	IC50 = 390 nM	[4]
	NSC-645808	Drug Info	IC50 = 10000 nM	[1]
	NSC-645827	Drug Info	IC50 = 700 nM	[1]
	NSC-65069	Drug Info	IC50 = 10000 nM	[4]
	NSC-73410	Drug Info	IC50 = 7500 nM	[1]
	NSC-99528	Drug Info	IC50 = 1100 nM	[4]
Action against Disease Model	Apaziquone	Drug Info	EO-9 induces a broad spectr uM of activity (IC50 values range from 8 to 590 ng ml-1) against a panel of h uMan and murine t uMour cell lines. Some evidence exists of selectivitytowards leukaemia and h uMan colon cell lines as opposed to murine colon cells. The response of cells to Mitomycin C were not comparable to EO-9 suggesting that the mechanism of action of these compounds is different. The cytotoxic properties of EO-9 under aerobic conditions are significantly influenced by extracellular pH. Reduction of pH from 7.4 to 5.8 increases cell kill from 40% to 95% in DLD-1 cells	[5]
References
REF 1	In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
REF 2	Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human panc... J Med Chem. 2007 Dec 13;50(25):6316-25.
REF 3	Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56.
REF 4	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
REF 5	In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity. Br J Cancer. 1992 Mar;65(3):359-64.
REF 6	Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. J Urol. 2006 Oct;176(4 Pt 1):1344-8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.